Short answer
ANI PHARMACEUTICALS INC (ANIP) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Updated investor presentation published November 16, 2026.
ANI PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated investor presentation published November 16, 2026
- Materials intended for investor and analyst meetings
- Exhibit 99.1 contains the presentation and may include updated company outlook or strategy័ត៌មាន
Item EX-99.1 · Exhibit EX-99.1
- 2026 guidance: revenue $1.085B-$1.125B, adjusted EBITDA $290M-$300M, adjusted EPS $9.37-$9.71
- Rare Disease expected to exceed 50% of 2026 revenue, accelerating ANI’s shift away from generics
- Cortrophin Gel guidance $480M-$500M, supported by gout expansion and a salesforce increase from ~120 to ~180 representatives
- Egetis acquisition would add EMCITATE, the only approved MCT8 treatment, with over $300M peak-sales potential
- Acquisition execution and commercialization remain key risks, while $420.8M cash and 0.7x net leverage provide financial flexibility
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANI PHARMACEUTICALS INC 8-K filings
Get the next ANIP 8-K as it lands
Follow ANIP for push alerts, or ask the research agent what this filing means.